Are semaglutide tablets good for weight loss?

You've seen the injection, now there's a tablet: here's the real difference

If you've been reading about Wegovy and wondering whether a daily tablet might suit you better than a weekly injection, you're asking a reasonable question. The Wegovy pill contains semaglutide, the same GLP-1 medicine that works by reducing appetite and slowing gastric emptying. The formulation, though, is genuinely different: the tablet uses an absorption enhancer called SNAC to carry semaglutide across the stomach lining, because GLP-1 peptides are normally broken down by digestive enzymes before they reach the bloodstream.

That process is why the morning routine matters so much. The tablet has to be taken alone, with no more than around 120ml of plain water, before any food, coffee or other medication. Your stomach needs to be empty and relatively still for the SNAC mechanism to work. It becomes habit quickly for most people (tablet before the kettle goes on, everything else after 30 minutes) but it is worth knowing in advance rather than finding out on day one.

No refrigeration is required. That alone makes a real practical difference for anyone who travels regularly or simply doesn't want a medical pen in the fridge door. You can read more about how the tablets compare to the injection on the semaglutide tablets for weight loss overview page.

What the trial numbers mean in plain terms

The OASIS 4 phase 3 trial followed 307 adults with obesity or overweight and at least one weight-related condition, without diabetes, over 64 weeks. All participants made lifestyle changes alongside treatment. The headline finding, published at the time of the MHRA's approval announcement in June 2026, was an average weight reduction of roughly 13.6% compared with about 2.4% in the placebo group. Among those who took every dose as prescribed throughout the trial, the average reached approximately 17%.

That distinction matters. The 13.6% figure is the real-world-style average across everyone who enrolled, including those who missed doses or dropped out. The 17% reflects full adherence, which not everyone achieves outside a controlled trial. Both numbers are worth knowing; neither is a guarantee of what you personally will lose. Weight loss with any GLP-1 medicine varies depending on starting weight, diet, activity, and how your body responds to the medicine. The MHRA's Wegovy approval communications provide useful context on the semaglutide evidence base if you want to read the regulatory perspective directly.

For comparison, if you're curious how the injection stacks up, our page on Wegovy weight loss tablets sets out the differences between the tablet and injection formats in more detail. The tablet's 13.6% average is lower, though the studies used different populations and durations, so direct comparison has limits. For many people, the practical convenience of a tablet outweighs a small gap in average efficacy, and for those who fully adhere, that gap narrows considerably.

Who this tablet is (and isn't) licensed for

The MHRA licence covers adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, or prediabetes. The tablets are taken alongside a reduced-calorie diet and increased physical activity, not as a standalone fix. Treatment is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive, and the medicine is not licensed for anyone under 18.

A prescriber reviews the full clinical picture before any prescription is issued. BMI alone does not decide suitability; your medical history, current medications, and any relevant conditions all come into the assessment. If you're specifically interested in the higher-strength option, our page on semaglutide 7mg tablets for weight loss explains where that dose sits within the titration schedule and what to expect at that stage. If you've come across the Rybelsus and weight-loss tablet distinction, that page covers exactly where the two products differ and why one cannot substitute for the other.

The NHS does not currently fund these tablets; a NICE appraisal would need to take place first. For now, access is by private prescription only. If you're thinking about what the tablets cost privately, current treatment pricing is shown on the treatment page rather than in article copy, since prices can change.

Common side effects and how most people experience them

The most frequently reported side effects in the OASIS 4 trial were gastrointestinal: nausea, diarrhoea, constipation, vomiting, and indigestion. Around 74% of participants on active treatment reported at least one GI side effect, compared with 42% on placebo. Most were mild to moderate and settled as the body adjusted, particularly after the dose stabilised.

The dose ladder builds gradually, starting at 1.5mg daily, stepping up through 4mg and 9mg to the 25mg maintenance dose, with at least a month at each level before moving up. That gradual titration exists specifically to reduce the likelihood of severe nausea during the early weeks. NHS guidance on semaglutide covers what to expect and when to contact a clinician in plain language.

Seek urgent medical help for severe or persistent stomach pain that spreads to your back, with or without vomiting, this can occasionally indicate pancreatitis, which the MHRA flagged in a January 2026 Drug Safety Update for GLP-1 medicines. Other reasons to contact a healthcare professional promptly include signs of an allergic reaction, significant dehydration from vomiting or diarrhoea, or any new or worsening symptoms you're not sure about. Side effects you experience can also be reported directly to the MHRA via the Yellow Card scheme, it's a simple online form and genuinely helps the regulator monitor medicines in real-world use.

If you'd like to explore the full picture of treatment options before deciding anything, check your eligibility with our prescribers, the consultation is free, and a named clinician reviews your answers the same day.